Alnylam Pharmaceuticals Inc is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference or RNAi. The company harnesses the RNAi pathway to create medicines known as RNAi therapeutics which consist of small interfering RNA or siRNA that silence messenger RNA implicated in disease pathways. Alnylam focuses on targeting genetically validated genes involved in human disease pathology using delivery platforms such as N-acetylgalactosamine conjugates and lipid nanoparticles to enable hepatic central nervous system and extrahepatic tissue delivery.

Alnylam generates revenue primarily through the sale of its six approved RNAi-based medicines including AMVUTTRA ONPATTRO GIVLAARI OXLUMO Leqvio and Qfitlia. The company also earns revenue from collaboration agreements with partners such as Novartis and Sanofi who commercialize Leqvio and Qfitlia respectively. Additional revenue streams include milestone payments royalties and funding from strategic alliances with Roche Regeneron and other collaborators.

The company operates through the following segments:

• TTR Franchise focuses on transthyretin mediated amyloidosis including both polyneuropathy and cardiomyopathy indications with approved products AMVUTTRA and ONPATTRO and investigational therapy nucresiran.

• Acute Hepatic Porphyria segment addresses AHP with the approved product GIVLAARI.

• Primary Hyperoxaluria Type 1 segment focuses on PH1 with the approved product OXLUMO.

• Hypercholesterolemia segment involves Leqvio developed and commercialized by collaborator Novartis targeting PCSK9 to reduce LDL-C.

• Hemophilia segment centers on Qfitlia being commercialized by collaborator Sanofi targeting antithrombin for hemophilia A and B.

• Hypertension segment includes zilebesiran an investigational RNAi therapeutic targeting angiotensinogen in collaboration with Roche.

• Complement-Mediated Diseases segment features cemdisiran targeting the C5 complement component in collaboration with Regeneron.

• Neuroscience segment includes mivelsiran targeting amyloid precursor protein for cerebral amyloid angiopathy and Alzheimer’s disease.

• Other Investigational Programs segment encompasses additional early and late-stage programs such as ALN-HTT02 for Huntington’s disease and ALN-6400 for bleeding disorders.

Alnylam holds a leading position in the RNAi therapeutics field having pioneered the clinical validation and commercialization of siRNA based medicines. The company competes with other RNAi focused firms such as Arrowhead Pharmaceuticals Arbutus Biopharma and Dicerna Pharmaceuticals as well as larger pharmaceutical companies developing antisense gene therapy and small molecule treatments for similar disease areas. Alnylam’s competitive advantages include its proprietary delivery platforms such as ESC+ GalNAc conjugates and C16 lipid ligands its deep pipeline of clinical programs and its strategic collaborations that provide funding development expertise and global commercialization reach.

Alnylam serves patients suffering from rare and prevalent genetic diseases across multiple therapeutic areas. The company’s customer base includes individuals with hereditary transthyretin mediated amyloidosis acute hepatic porphyria primary hyperoxaluria hypercholesterolemia hemophilia hypertension complement mediated diseases and neurodegenerative conditions. Specific customer names are not disclosed in the filing as the company sells through healthcare providers pharmacies and specialty distributors rather than directly to end patients.